Immix Biopharma, Inc. (IMMX)

Immix Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	93.93	17.68	17.51	13.44	17.64
Short-Term Investments	6.48	-	-	-	-
Cash & Short-Term Investments	100.41	17.68	17.51	13.44	17.64
Cash Growth	467.86%	0.98%	30.31%	-23.85%	4411.66%
Other Receivables	-	1.97	1.17	0.26	0.03
Total Trade Receivables	-	1.97	1.17	0.26	0.03
Other Current Assets	0.83	0.54	1.11	1.21	0.52
Total Current Assets	101.24	20.2	19.79	14.9	18.19
Net Property, Plant & Equipment	3.49	2.73	0.05	0	0.01
Other Long-Term Assets	0.11	0.02	0.09	0.01	-
Total Assets	104.84	22.95	19.93	14.91	18.19
Accounts Payable	9.97	8.62	3.72	1.27	0.14
Accrued Expenses	-	-	-	-	0.01
Short-Term Debt	-	-	-	-	0.05
Current Portion of Leases	0.14	0.07	-	-	-
Total Current Liabilities	10.11	8.69	3.72	1.27	0.2
Long-Term Leases	0.93	1.01	-	-	-
Other Long-Term Liabilities	-	-	-	0.48	-
Total Long-Term Liabilities	0.93	1.01	-	0.48	-
Total Liabilities	11.04	9.7	3.72	1.75	0.2
Common Stock	0.01	0	0	0	0
Treasury Stock	-0.1	-0.1	-0.1	-0.1	-
Additional Paid-in Capital	198.29	88.37	69.78	51.16	47.62
Accumulated Other Comprehensive Income	0.06	-0	0.13	0.09	0.13
Retained Earnings	-104.46	-75.02	-53.41	-37.99	-29.76
Total Common Shareholders' Equity	93.8	13.25	16.41	13.16	17.99
Minority Interest	-	-	-0.2	-	-
Shareholders' Equity	93.8	13.25	16.2	13.16	17.99
Total Liabilities & Equity	104.84	22.95	19.93	14.91	18.19
Total Debt	1.07	1.07	0	0	0.05
Net Cash (Debt)	99.34	16.61	17.51	13.44	17.59
Net Cash Growth	498.15%	-5.16%	30.31%	-23.63%	-
Net Cash Per Share	3.01	0.59	1.01	0.97	4.79
Book Value	93.8	13.25	16.41	13.16	17.99
Book Value Per Share	2.85	0.47	0.95	0.95	4.90
Tangible Book Value	93.8	13.25	16.41	13.16	17.99
Tangible Book Value Per Share	2.85	0.47	0.95	0.95	4.90

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q